Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A Jackson

Showing results (221-230 of 246) with videos related to

Pageof 25
Sort By:
The Journal of Infectious Diseases|May 19, 2016
Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015Brendan Flannery, Richard K Zimmerman, Larisa V Gubareva, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
The New England Journal of Medicine|April 6, 2021
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19Nicole Doria-Rose, Mehul S Suthar, Mat Makowski, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Vaccine|October 25, 2025
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalinkJames G Donahue, Noelle M Cocoros, Burney A Kieke, et al.
Science Translational Medicine|February 25, 2026
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boostNoemia S Lima, Lauren McCormick, Samuel Li, et al.
The New England Journal of Medicine|December 3, 2020
Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationAlicia T Widge, Nadine G Rouphael, Lisa A Jackson, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
The New England Journal of Medicine|July 15, 2020
An mRNA Vaccine against SARS-CoV-2 - Preliminary ReportLisa A Jackson, Evan J Anderson, Nadine G Rouphael, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Pageof 25

Showing results (221-230 of 246) with videos related to

Sort By:
Pageof 25
The Journal of Infectious Diseases|May 19, 2016
Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015Brendan Flannery, Richard K Zimmerman, Larisa V Gubareva, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
The New England Journal of Medicine|April 6, 2021
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19Nicole Doria-Rose, Mehul S Suthar, Mat Makowski, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Vaccine|October 25, 2025
Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalinkJames G Donahue, Noelle M Cocoros, Burney A Kieke, et al.
Science Translational Medicine|February 25, 2026
The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boostNoemia S Lima, Lauren McCormick, Samuel Li, et al.
The New England Journal of Medicine|December 3, 2020
Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationAlicia T Widge, Nadine G Rouphael, Lisa A Jackson, et al.
The New England Journal of Medicine|September 22, 2021
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
The New England Journal of Medicine|July 15, 2020
An mRNA Vaccine against SARS-CoV-2 - Preliminary ReportLisa A Jackson, Evan J Anderson, Nadine G Rouphael, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
Pageof 25